Flexible Solutions International is a small, profitable Alberta company whose thesis has quietly changed: it started as a maker of biodegradable thermal polyaspartate polymers for oilfields, fertilizer, and detergents, and it is now converting that same polymer chemistry into confidential, food grade manufacturing for two large customers, with a new Panama plant taking over the legacy industrial lines and freeing the Illinois plant to run almost entirely for food and nutrition contracts.
The most important development is the second major food grade contract disclosed on the first quarter 2026 call: a five year agreement with a minimum revenue of 6.5 million per year and tariff and inflation protection, now running the Illinois plant around the clock. The ceiling on the contract sits above 25 million. The mechanism matters because it turns a plant with two years of idle equipment into a contracted producer, so the cost of scaling is already spent and the remaining capital need to reach 13 to 15 million in annual sales is small. For shareholders, the consequence is that the next several quarters convert fixed cost into margin, and the consequence for the thesis is that the stock is now a story about two confidential customer relationships rather than a story about polymer pricing.
The central tension is that the second quarter 2026 printed a net loss of 1.9 million, a year over year swing from profit to loss. Revenue for the quarter was 7.6 million. The company guides to stronger quarters ahead, but the loss quarter is the number in front of the reader. The mechanism is the front loaded cost of scaling two new operations at once, the Panama start up and the Illinois food ramp, against a year earlier quarter that carried a one time R and D services payment of 2.5 million. Shareholders are being asked to price the second half ramp on the strength of management words, and the risk is that food margins, which management targets in the low twenties before tax, stay below that range long enough to make the transition a loss machine.
The catalyst is the third quarter 2026 report. Management has set out explicit hopes for that quarter. Panama is to contribute 3 million in revenue. The ENP division is to exceed 5 million, and the food division is to exceed 4 million. The print is the first hard test of the ramp.
The company was incorporated in 1991 in British Columbia. It moved to Nevada in 1998 and re domiciled to Alberta, Canada in 2019, and it trades on the NYSE American. The business assembles around four product lines: thermal polyaspartates, or TPAs, which make up the bulk of revenue; nitrogen conservation products for agriculture; evaporation control products for pools, spas, and water bodies; and, newest, food and nutrition manufacturing. The TPA chemistry is a biodegradable, water soluble polymer made from the amino acid L aspartic, and it is the technical core of every other line because the food products are themselves polyaspartate based. The company holds the intellectual property it acquired in 2004 from the bankruptcy estate of Donlar Corporation, 52 U.S. and 139 international patents, together with a 56,780 square foot plant near Chicago that became the operating base of the NanoChem subsidiary.
The strategic structure is two plants with two jobs. The NanoChem plant in Peru, Illinois, is the legacy TPA and now the food grade facility, and it is FDA and SQF certified. The Panama plant, built by the Panama Chem Solutions subsidiary, is the new home of the legacy industrial and agricultural TPA lines, plus the nitrogen conservation products SUN 27 and N Savr 30. The point of the split is geographic and regulatory: international sales ship from Panama without U.S. tariff exposure on the inbound raw materials, and the freed Illinois capacity is dedicated to food and nutrition, a higher value, higher contract security use of the same polymer. Management has said the migration is step by step and that by the end of 2026 the Illinois plant is to be focused entirely on food grade products.
The customer base is the most consequential feature of the business and also the most opaque. For the six months ended June 30, 2026, a single new food grade customer dominated the sales mix. It accounted for 29 percent of the six month total. The concentration reflects two large signed contracts rather than a broad base of small orders. The three primary customers together made up 54 percent. In full year 2025, the largest customer accounted for 8.8 million in sales. Total sales for the year were 38.5 million. The concentration is the reason the ramp can be as fast as it is, because a small number of large relationships drive the volume. That concentration is a double edge: it is the reason the revenue ramp can be as fast as it is, because a few large relationships drive the volume, and it is also the reason a single contract slip is a company level event rather than a line item.
The competitive field is small and asymmetric. In TPAs, the main named competitor is Lanxess, the German specialty chemicals maker that uses a different patented process. In nitrogen conservation, the products are sold through distributors in North and South America, some under private label. In food grade polyaspartate ingredients, the field is thinner still, and the company's FDA and SQF certification plus the two large contracts it has already signed put it in a position it describes as being chosen by its customers, with the contracts carrying tariff and inflation protection clauses that the company says it would not have obtained without giving up some margin. The moat is therefore less about the chemistry, which is protected by patents, and more about the certification, the installed base of equipment, and the signed contracts.
The technical core is the thermal polyaspartate chemistry. The polymer is made by thermally polymerizing L aspartic acid, an amino acid the company imports from China, and the process yields a family of variants that are tuned for a given use. For oilfields, the TPA acts as a scale and corrosion inhibitor in topside water systems and in frac fluids, replacing phosphonate products where biodegradability is required by regulation. For agriculture, it reduces fertilizer crystallization in the soil and delays the formation of crystals between fertilizer and soil minerals, which keeps nutrients available to the plant and lifts yield in the target crops. For cleaning products, it replaces polyacrylate, which is not biodegradable, as the soil re deposition preventer. The same molecule, in other words, is sold into four industries, and that is the reason the company can pivot a plant from one industry to another without abandoning the chemistry.
The nitrogen conservation line is a related but distinct application. SUN 27 slows the bacterial degradation of applied nitrogen, and N Savr 30 addresses the denitrification pathway where bacteria strip oxygen from the fertilizer and release the nitrogen to the atmosphere as a gas. Both are sold through distributors under the company's own names and under private label, and both are now made in Panama, which means the agricultural line is now produced on the same plant as the legacy industrial TPA, a consolidation that reduces the number of sites the company has to staff and maintain.
The food grade line is the new strategic center. The company has commercialized two food products to date, a wine additive based on polyaspartates and a second product that is the subject of the August 2025 contract. That contract carries a minimum revenue of 6.5 million per year, with tariff and inflation protection built into the pricing. The ceiling sits above 25 million. A third, larger food grade contract was announced in January 2025. Its production has been ramping up through the first half of the year, and the customer now accounts for 29 percent of company sales. The equipment for these contracts was bought and installed over the prior two years without a committed customer. That is why the additional capital needed to scale the August 2025 contract is small. The step to the 25 million ceiling sits in the low single digit millions range.
The moat is a stack of four things. The first is the patent portfolio, 191 patents acquired from Donlar, which is the legal barrier to a direct chemical copy. The second is the FDA and SQF certification on the Illinois plant, which is the regulatory barrier to a food grade entrant and takes years to build. The third is the installed equipment, which is a sunk cost that a competitor would have to replicate before it could take the contracts. The fourth, and the most important, is the signed contracts themselves, which lock in the revenue for a period of years and carry the tariff and inflation clauses that make the economics of the contract stable even in a volatile input cost environment. The combined effect is that the company's next several quarters are largely a matter of production schedule rather than sales development, which is a very different risk profile from a typical small cap growth company.
Full year 2025 printed total sales of 38.5 million, which excluded the one time R and D services fee from a project that completed that year. Gross profit was 12.5 million, or 32.6 percent of total sales. The gross margin was the highest in the company's recent history, and the year also carried the building sale gain and the Lygos impairment on the income statement. Net income was 2.4 million, and the allocation of that figure is the first structural wrinkle in the result. The results included a gain of 1.2 million on the sale of the Mendota building. A write down of 183 thousand was recorded on the property held for sale at Mendota, Illinois. The company paid a special dividend of 0.10 per share in the spring.
The first half is where the story turns. Revenue was 15.9 million, down from the year earlier period. The gap is mostly the one time R and D services payment that does not repeat. Product revenue was down year over year. Cost of sales rose to 14.3 million, up from a year earlier. The gross margin fell to 10.1 percent. That is a compression of nearly 30 points, the single most important data point in the financial story. It is the number the second half has to reverse. The company attributes the compression to the additional man hours, equipment maintenance, and utility costs of scaling up the new food grade product in Illinois and the start up of the Panama plant. Management expects the compression to end in the third quarter. The second quarter alone was a loss. Revenue was 7.6 million against cost of sales of 7.9 million. The quarter closed with a gross loss. The net loss attributable to the controlling interest was 1.9 million, or 0.15 per share. The year earlier quarter had been a profit.
The balance sheet is the quiet strength of the story. As of the end of the first half, the company held 7.2 million in cash, with the rest of the cushion in term deposits. Total assets were 59.0 million and total liabilities were 18.1 million. The balance sheet carries a net cash position, and the debt load is light by small cap standards. Long term debt was 3.8 million, down from 4.0 million a year earlier. The company paid off the ENP acquisition loan in the spring and a three year equipment note in the fall. That combination freed up over 2 million a year in cash flow. working capital of 18.7 million is a comfortable cushion for a small cap balance sheet. The company has no material debt maturities coming due, and it says it has no equity financing commitments, which means the ATM shelf it registered earlier this year is a contingency rather than a plan.
The customer concentration is the number that matters most for the next four quarters. A single food grade customer was 29 percent of first half sales. The three primary customers together were 54 percent. In full year 2025, the largest customer was 8.8 million. By mid year it had fallen to 222 thousand. The decline is a sign that the customer is paying on time and that the receivable build that had been a working capital drag is reversing. The cash flow from operations for the first half was 3.5 million, down from 4.7 million a year earlier. The decline was driven by the build in inventory, which rose by 4.6 million in the period, as the company stocks up for the second half ramp.
The forward story is a ramp with three moving parts, and management has, against its usual practice of giving no guidance, disclosed specific revenue hopes for the third quarter of 2026. The Panama division is expected to contribute 3 million in revenue. The ENP division is expected to exceed 5 million, and the NanoChem division, which now carries the food contracts, is expected to exceed 4 million. Taken together, those three figures imply a third quarter revenue of roughly 12 million, which would be the strongest quarter in company history and would mark the point at which the food and Panama lines have moved from start up to production. The fourth quarter is the repeat of that print with the benefit of a full season of ENP, which is the division's growth period. The company has said the Panama migration is to be complete by the end of the year, after which the Illinois plant runs entirely on food contracts. That is the point at which the two plants have fully assumed their respective roles in the business.
The first quarter 2026 call is the most useful single document for the execution picture, and it named several events that actually happened and that shape the next year. The most significant was the second major food grade contract, signed in August 2025, which reached full production and is now running the Illinois plant around the clock. The mechanism of that contract is the tariff and inflation protection clause, which means the company's input cost exposure is capped by the contract pricing, and the consequence for shareholders is that the margin on that contract is fixed at a level management describes as lower than preferred, in the low twenties before tax, in exchange for the revenue certainty of a five year minimum. The third, larger food contract, signed in January 2025, has been in small volume production through the first half. It is the line item that management expects to show significant revenue in the second and third quarters of 2026, and the customer now sits at 29 percent of company sales.
The Panama plant start up is the second execution event. Shipments began in January 2026, and the plant has been absorbing start up costs, additional training man hours, and higher utility expense through the first half, all of which management expects to taper off in the third quarter. The strategic point of the Panama plant is that it removes the U.S. tariff exposure from the international sales channel, because the inbound raw materials are sourced without U.S. tariffs and the finished goods ship from a port 30 minutes from the plant rather than across the United States. The consequence for shareholders is that the company's international revenue, which is the legacy TPA and nitrogen lines, should carry a structurally lower cost of goods in the second half of 2026 and beyond, and the consequence for the thesis is that the company's two divisions are now optimized for different geographies, with Illinois serving U.S. food customers and Panama serving the international industrial and agricultural base.
The tariff environment is the third execution variable. The company's raw material imports from China carry tariffs in the range of 15 to 58.5 percent depending on the material, and management has said it stays careful not to import materials unless they are destined for U.S. customers who are guaranteed to buy and are aware that the tariff is added to the invoice. The consequence of that policy is that the company's U.S. facing product lines carry a higher landed cost than their competitors who source elsewhere, and the Panama plant is the structural answer to that problem for the international lines. The risk is that the tariff environment remains volatile, and that the company's food customers, who are paying a fixed price under the tariff protection clause, end up in a position where the company's cost of goods is higher than the contract price allows.
The first and largest risk is customer concentration. A single food grade customer is 29 percent of company sales, and the three primary customers are 54 percent. The mechanism of that risk is that the revenue ramp is entirely dependent on the production schedule of two or three confidential relationships, and the consequence for shareholders is that a single contract slip, a single quality rejection, or a single customer's own demand shift is a company level event. The company has no diversified base to absorb that kind of shock, and the receivable history, with the largest customer carrying 6.7 million at year end 2025, shows that the working capital is also concentrated in the same relationships.
The second risk is the margin compression that the company is currently in. The first half of 2026 gross margin was 10.1 percent. A year earlier it had been 39 percent. The second quarter was a gross loss. The mechanism is the front loaded cost of scaling two operations at once, and the consequence for shareholders is that if the taper off in the third quarter does not arrive as management expects, the company enters the second half of 2026 still running at a gross loss, which would change the character of the story from a ramp to a cost problem. The company's own description of the food margins, in the low twenties before tax, is a level that is well below the 32.6 percent gross margin the company ran in full year 2025, and the mix shift toward food is therefore a structural margin dilution even in the best case.
The third risk is the non controlling interest structure. The ENP and Mendota entities carry a non controlling interest, and in the most recent fiscal year that interest took 1.6 million of the 2.4 million in net income. That is 66 percent of the total. That structure means a substantial share of the company's earnings is allocated to parties that are not the public shareholders. The consequence for shareholders is that the per share number is a smaller slice of the company's actual economic profit than the headline net income would suggest, and the mechanism is that the ENP division, which is the golf, turf, and ornamental line, is held in a limited liability company structure that has outside owners. The company has been distributing to the non controlling interest each year. The payments were 992 thousand in the most recent year and 795 thousand the year before. That outflow is a permanent feature of the capital structure.
The fourth risk is the audit transition and the board change that both happened in the second half of the year. The company changed its independent auditor from Assure CPA to Sadler Gibb in the spring, with the change approved by the audit committee. The new auditor brings a different style of review to the reporting process, and the transition year is when the two styles meet for the first time. The company also replaced a long serving director, John Bientjes, who served nearly three decades and was the audit committee chair, with Dr. Kim Reid, a process development scientist with a background in bio manufacturing and mRNA technology transfer. The mechanism of the auditor change is not disclosed in detail, and the consequence for shareholders is that the transition year carries a higher risk of reporting friction. The board change, while the company describes the departure as not due to any disagreement, removes a director who was the institutional memory of the audit function and replaces that memory with a scientist whose expertise is in a different industry. The combined effect is that the governance layer of the company is in flux in the same year that the operating layer is in the middle of a major transition, and that is a risk that is hard to price but worth naming. The counterargument to the bull case runs through all four of these risks at once. The company is a small cap with a single large customer, a margin profile in structural transition, a non controlling interest that takes two thirds of the earnings, and a governance layer in flux. The stock, which has nearly doubled from its level a year ago, already prices in a ramp that has not yet shown up in a printed quarter. The stock traded in the 3 to 4 range earlier in the year. It then reached a high of 11.25 in the summer. It then settled into the 5 to 6 range. The current level is well above the 1.91 close of 2023, a move over the full period that is close to a tripling. The bear case is that the ramp stalls in the second half of the year, the food margin stays below the low twenties, and the stock re rates to a multiple that reflects a company with a single large customer and a margin in transition rather than a company with a diversified, high margin food ingredients platform.
The market values the company at roughly 73 million. That is 5.70 per share. The multiple framework has to be built around the company's own guidance rather than a trailing earnings number, because the trailing number is distorted by the one time items and the first half loss. The share count is 12.8 million. The cleanest base is the full year product sales of 36.0 million. The cleanest earnings number is the net income attributable to the controlling interest of 0.79 million, or 0.06 per share. The underlying operating earnings, stripped of the one time items, run in the 1.5 to 2.0 million range.
On a bear case, the ramp stalls in the second half, and the food margin holds in the low teens rather than the low twenties. The company enters 2027 with product sales of roughly 42 million. Controlling interest net income in that case is roughly 1.2 million, or 0.09 per share. At a multiple of 20 times that earnings, which is a multiple in line with a small cap that has a single large customer and a margin in transition, the implied value is 2.40 per share. That is a 58 percent decline from the current price. The bear case is the case where the stock re rates to a multiple that reflects what the company is, a concentrated small cap with a margin in transition, rather than what the ramp promises.
On the base case, the ramp proceeds as management has described. The third quarter prints at or above the 12 million implied by the three division hopes, and the food margin reaches the low twenties by the fourth quarter. The company enters 2027 with product sales of roughly 50 million. Controlling interest net income in that case is roughly 2.5 million, or 0.20 per share. At a multiple of 25 times that earnings, which is a multiple that reflects a company with two signed food contracts and a Panama plant that removes the tariff exposure from the international lines, the implied value is 5.00 per share, which is close to the current price. The base case is the case where the stock is fairly valued and the next catalyst is the second half 2026 print.
On the bull case, the ramp accelerates. The food margin reaches the upper end of the low twenties, the Panama plant contributes more than the low single digit millions in the second half, and the company signs a third major food customer in the first half of next year. In that case, the company enters the next fiscal year with product sales of roughly 60 million. The controlling interest net income is roughly 3.5 million. At a multiple of 30 times that earnings, which is a multiple that reflects a company with a diversified food ingredients platform and a structural cost advantage from the Panama plant, the implied value is 8.10 per share. That is a 42 percent gain from the current price. The multiple analysis carries three named variables from the framework to the conclusion. The first is the food margin, which is the single most important number and which management has described as being in the low twenties before tax. The spread between that number and the current first half gross margin is the entire value of the ramp. The second is the third quarter revenue, which is the first hard test of the ramp and which management has set at a level that implies roughly 12 million. The spread between that number and the second quarter revenue of 7.6 million is the visible part of the acceleration. The third is the non controlling interest take, which is 66 percent of net income and which is a permanent feature of the capital structure. The spread between that number and a lower take, which would require a buyout of the ENP non controlling interest, is the hidden part of the per share story. The bear case is the case where all three variables come in at the low end. The base case is the case where they come in at the management described level, and the bull case is the case where the food margin and the third quarter revenue both come in at the high end and the non controlling interest take is reduced.
The judgment on this dispatch is that Flexible Solutions International is a company in the middle of a genuine, verifiable transformation, and that the transformation is more real than the small cap profile would suggest. The company has signed two large food contracts, built a second plant, paid off its major debt, and reduced its customer receivables, and those are facts that are in the public record rather than in management commentary. The stock is not a story about a polymer, it is a story about a plant that is being converted into a food ingredient shop, and the plant is the asset that carries the thesis.
The central question is whether the margin conversion that the ramp is supposed to deliver actually arrives in the second half of 2026, and that question is answerable in the coming months rather than in the next year. The company has set out specific revenue hopes for the third quarter, and the fourth quarter print is the point at which the base case and the bear case diverge in a visible way. The stock at 5.70 is priced for a ramp that has not yet printed, and that is a reasonable price if the ramp arrives and an expensive price if it does not. The governance layer is in flux in the same year that the operating layer is in transition, and that is a risk that is worth carrying in the multiple rather than ignoring.
The final assessment is that the company is a small, real business with a genuine transformation in progress, and that the next two prints are the test of whether the transformation is a margin story or a cost story. The valuation framework is built around the three named variables, the food margin, the third quarter revenue, and the non controlling interest take, and the spread between the bear and the bull is the spread between a 2.40 and an 8.10, which is a wide spread that reflects a company whose future is not yet in the filings. The honest read is that the stock is fairly valued on the base case, cheap on the bull case, and expensive on the bear case, and that the next two quarters are the arbiter between those three.